Transcode Therapeutics Files Amendment to S-1 Registration Statement

TL;DR

<b>Transcode Therapeutics, Inc. has filed an amendment to its S-1 Registration Statement, indicating ongoing efforts related to securities offerings.</b>

AI Summary

Transcode Therapeutics, Inc. (RNAZ) filed a Amended IPO Registration (S-1/A) with the SEC on January 17, 2024. Transcode Therapeutics, Inc. filed an amendment to its Form S-1 Registration Statement on January 17, 2024. The filing is in relation to the Securities Act of 1933. The company's principal executive offices are located at 6 Liberty Square, #2382, Boston, MA 02109. Thomas A. Fitzgerald is the Interim Chief Executive Officer. The registration statement number is 333-276467.

Why It Matters

For investors and stakeholders tracking Transcode Therapeutics, Inc., this filing contains several important signals. This amendment suggests the company is actively pursuing capital raising or other securities-related transactions, which could impact its financial structure and future operations. The filing provides updated information for potential investors and regulatory bodies, reflecting the company's current status and plans.

Risk Assessment

Risk Level: low — Transcode Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate significant new risks or positive developments.

Analyst Insight

Monitor future filings for details on the proposed securities offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 2024-01-17 — Filing Date (As filed with the U.S. Securities and Exchange Commission)
• 333-276467 — Registration Number (Registration No.)
• 6 Liberty Square, #2382 — Principal Executive Offices Address (Address of Registrant's principal executive offices)
• Boston, MA 02109 — Principal Executive Offices City/State/Zip (Address of Registrant's principal executive offices)
• 857-301-6857 — Business Phone Number (Business Phone)

Key Players & Entities

• Transcode Therapeutics, Inc. (company) — Registrant
• Thomas A. Fitzgerald (person) — Interim Chief Executive Officer
• Goodwin Procter LLP (company) — Legal Counsel
• Ellenoff Grossman & Schole LLP (company) — Legal Counsel
• Michael Bison (person) — Legal Counsel
• Finnbarr Murphy (person) — Legal Counsel
• John J. Hart, Esq. (person) — Legal Counsel
• 333-276467 (registration_number) — Registration No.

Forward-Looking Statements

• Transcode Therapeutics will proceed with a public offering of securities under Rule 415 in the near future. (Transcode Therapeutics, Inc.) — high confidence, target: Q1 2024
• The offering will likely be for general corporate purposes, including funding ongoing pharmaceutical research and development. (Transcode Therapeutics, Inc.) — medium confidence, target: N/A

FAQ

Industry Context

The company operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track subsequent SEC filings for updates on the registration statement's effectiveness and offering progress.
3. Analyze the company's business strategy and financial health in light of the potential securities offering.

Key Dates

• 2024-01-17: Filing of Amendment No. 1 to Form S-1 — Indicates an update or addition to the company's registration statement for securities.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating an update to the initial filing rather than a new registration.

Key Financial Figures

• $5 — anying common stock purchase warrant is $5.00, which was the closing price of our
• $ — ill have an exercise price per share of $, will be exercisable upon issuance and
• $0 — d to the public in this offering, minus $0.01, and the exercise price of each pre-
• $0.01 — rice of each pre-funded warrant will be $0.01 per share. For each pre-funded warrant
• $5.00 — Capital Market on January 12, 2024, was $5.00 per share, adjusted for the 2024 Revers
• $2,500,000 — intain stockholders' equity of at least $2,500,000. The Nasdaq Hearings Panel has informed
• $50,000 — accountable expenses in an amount up to $50,000, legal fees and other out-of-pocket exp
• $100,000 — -pocket expenses in the amount of up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $136.9 billion — r treatment market is expected to reach $136.9 billion by 2032 (July 6, 2023 /PRNewswire/ —All

Filing Documents

• tm2333928-3_s1a.htm (S-1/A) — 3510KB
• tm2333928d4_ex3-3.htm (EX-3.3) — 8KB
• tm2333928d4_ex4-2.htm (EX-4.2) — 106KB
• tm2333928d4_ex4-3.htm (EX-4.3) — 112KB
• tm2333928d4_ex4-4.htm (EX-4.4) — 109KB
• tm2333928d4_ex5-1.htm (EX-5.1) — 13KB
• tm2333928d4_ex10-13.htm (EX-10.13) — 40KB
• tm2333928d4_ex10-14.htm (EX-10.14) — 212KB
• tm2333928d4_ex23-1.htm (EX-23.1) — 2KB
• lg_transcodetheraptm-4c.jpg (GRAPHIC) — 10KB
• fc_therapeutics-4clr.jpg (GRAPHIC) — 43KB
• fc_currentpipeline-4clr.jpg (GRAPHIC) — 35KB
• fc_therapeutic-4clr.jpg (GRAPHIC) — 60KB
• fc_figure1-4clr.jpg (GRAPHIC) — 93KB
• fc_figure2-4clr.jpg (GRAPHIC) — 46KB
• fc_figure3-4clr.jpg (GRAPHIC) — 211KB
• fc_figure4-4clr.jpg (GRAPHIC) — 120KB
• fc_figure5-4clr.jpg (GRAPHIC) — 111KB
• fc_figure6-4clr.jpg (GRAPHIC) — 67KB
• fc_figure7-4clr.jpg (GRAPHIC) — 50KB
• fc_figure8-4clr.jpg (GRAPHIC) — 93KB
• lc_figure9-4clr.jpg (GRAPHIC) — 69KB
• lc_figure10-4clr.jpg (GRAPHIC) — 59KB
• fc_figure11-4clr.jpg (GRAPHIC) — 76KB
• lc_figure12-4clr.jpg (GRAPHIC) — 53KB
• fc_figure13-4clr.jpg (GRAPHIC) — 65KB
• fc_figure14-4clr.jpg (GRAPHIC) — 100KB
• lc_figure15-4clr.jpg (GRAPHIC) — 30KB
• 0001104659-24-004279.txt (&nbsp;) — 6031KB

Risk Factors

Risk Factors 24 Cautionary Note Regarding Forward-Looking Statements 90 Industry and Other Data 92

Use of Proceeds

Use of Proceeds 94 Dividend Policy 95 Capitalization 96

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 100

Business

Business 122 Management 172

Executive Compensation

Executive Compensation 180 Certain Relationships and Related Party Transactions 186 Principal Stockholders 187

Description of Capital Stock

Description of Capital Stock 189 Material U.S. Federal Income Tax Considerations 199 Plan of Distribution 206 Legal Matters 209 Experts 209 Index to Financial Statements F-1 Neither we nor the placement agent have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on our behalf or to which we have referred you. We and the placement agent take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We and the placement agent are offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and future prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. We and the placement agent are offering to sell, and seeking offers to buy, our shares of common stock and pre-funded warrants only in jurisdictions where offers and sales are permitted. Neither we nor the placement agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United

View Full Filing

View this S-1/A filing on SEC EDGAR